HILE(SH:603718) Ge Long Hui A P P·2025-11-30 08:37Core Viewpoint - The company, Haili Biological, has agreed to accept equity in a subsidiary as compensation for a transaction price difference due to the financial difficulties faced by Meilun Company [1] Group 1: Transaction Details - On November 21, 2025, Haili Biological received a communication from Meilun Company indicating an inability to repay the transaction price difference on time [1] - Meilun Company proposed to settle the transaction price difference by transferring 41% equity in Shaanxi Ruisheng Biological Technology Co., Ltd. to Haili Biological [1] - The equity transfer is valued at 399.3 million yuan, based on an asset evaluation report that values Ruisheng Biological's total equity at 974 million yuan [1] Group 2: Ownership Changes - Following the completion of this transaction, Haili Biological's ownership in Ruisheng Biological will increase from 55% to 96%, maintaining it as a subsidiary [1]